Pharmaceutical News

RSS

USPTO issues patent for Avila's targeted covalent drugs portfolio

Avila Therapeutics, Inc., a biotechnology company developing targeted covalent drugs that treat diseases through protein silencing, announced today that the United States Patent and Trademark Office has issued Patent No. 7,982,036, "4,6-Disubstituted Pyrimidines Useful as Kinase Inhibitors."

21 Jul 2011

AstraZeneca receives FDA approval for BRILINTA to treat acute coronary syndrome

AstraZeneca announced today that the US Food and Drug Administration (FDA) has approved BRILINTA (ticagrelor) tablets to reduce the rate of heart attack and cardiovascular (CV) death in adult patients with acute coronary syndrome (ACS), compared to clopidogrel.

21 Jul 2011

FDA approves AstraZeneca's anti-clotting drug Brilinta

The U.S. Food and drug Administration (FDA) has finally approved AstraZeneca's Brilinta blood thinner for patients with acute coronary syndrome - conditions, such as heart attack and angina.

20 Jul 2011

FDA panel votes against novel diabetes drug citing adverse effects

An advisory panel for the US Food and Drugs Administration voted 9-6 that the FDA should not yet approve dapagliflozin, a new type of diabetes drug that makes the body dump sugar and lose weight. Signals of possible liver damage and of breast and bladder cancer worried the experts.

20 Jul 2011

Purdue Pharma develops new online resource for combating prescription drug abuse

A new online resource, RxSafetyMatters.org, is now available to help healthcare professionals, law enforcement, and community organizations combat the illegal diversion and abuse of prescription medications.

20 Jul 2011

VIVUS to present topiramate exposure, birth defect data at IEC

VIVUS, Inc. today announced that on August 31, 2011, during the late breaking poster session at the 29th International Epilepsy Congress in Rome, Italy, Dr. Alison Pack, Associate Professor of Clinical Neurology, Department of Neurology, Columbia University Medical Center, will present the results of a retrospective study of medical claims data on oral clefts (OC) and major congenital malformations (MCMs) associated with in utero topiramate exposure.

20 Jul 2011

Capsules: IOM recommends free birth control for all

Today on the Capsules blog, Jenny Gold writes: American women ought to be able to get their birth control for free, according to a new report from the Institute of Medicine.

20 Jul 2011

Birth control pills may reduce woman's bone density

Birth control pills may reduce a woman's bone density, according to a study published online July 13 in The Journal of Clinical Endocrinology and Metabolism by Group Health Research Institute (GHRI) scientists.

20 Jul 2011

New transgenic mouse could predict toxicity of targeted cancer drugs

Only one in twenty cancer drugs makes its way from the laboratory to become an approved pharmaceutical product. The majority of new agents are only shown to be unsuitable in the later phases of clinical development which would explain the exorbitantly high development costs of 500 to 600 million euros per new cancer drug.

20 Jul 2011

Valeant, sanofi-aventis partner to market and distribute Zuacta cream

Valeant Pharmaceuticals International, Inc. announced today that its subsidiary, Valeant International SRL, has entered into an agreement with sanofi-aventis Canada Inc.

20 Jul 2011

Patients who use anti-depressants more likely to suffer relapses

Patients who use anti-depressants are much more likely to suffer relapses of major depression than those who use no medication at all, concludes a McMaster researcher.

20 Jul 2011

CEL-SCI expands licensing agreement with Teva for Multikine cancer drug

CEL-SCI Corporation announced today that it has expanded the licensing agreement with Teva Pharmaceutical Industries Ltd. for its cancer drug Multikine.

20 Jul 2011

DNA vaccine developer Coridon in U.S. collaboration

DNA vaccine development company Coridon Pty Ltd. today announced that it has entered into a research collaboration agreement with The Ohio State University to progress its Epstein Barr Virus (EBV) project.

19 Jul 2011

Natural formula can fight against highly invasive breast cancer

Researchers at Indiana University and Methodist Research Institute have published the dramatic effects of a natural formula against breast cancer. The impressive results are found in the latest issue of the peer-reviewed journal, Integrative Cancer Therapies.

19 Jul 2011

Thalidomide analog shows promise against sickle cell disease

A thalidomide analog is shaping up as a safe, worthy opponent of sickle cell disease, Georgia Health Sciences University researchers report.

19 Jul 2011

Catylix, Illinois enter license agreement to incorporate fluorine into drugs

Catylix, Inc. and the University of Illinois at Urbana-Champaign have entered into a license agreement under which Catylix will utilize a technology developed by Illinois' Professor John Hartwig to quickly and efficiently introduce fluorine and fluorine-containing substituents into molecules.

19 Jul 2011

Anti-malaria drug provides key insight into potential treatments for autoimmune diseases

In a study published recently in the journal Science Signaling Van Andel Research Institute (VARI) scientists demonstrate on the molecular level how the anti-malaria drug chloroquine represses inflammation, which may provide a blueprint for new strategies for treating inflammation and a multitude of autoimmune diseases such as arthritis, multiple sclerosis, and certain cancers.

19 Jul 2011

U.S. Patent Office issues Notice of Allowance for Kuros' PTH to improve bone healing

Kuros Biosurgery AG, a biotechnology company focused on the development of novel biomaterials and bioactive-biomaterial combination products for trauma, wound and spinal indications, announced today that it has received Notice of Allowance for U.S. 11/679,807 from the U.S. Patent Office.

19 Jul 2011

International Journal of Cancer publishes Bionovo's Bezielle research

Bionovo, Inc., a pharmaceutical company focused on the discovery and development of safe and effective treatments for women's health and cancer, today announced the publication of a study of the metabolic effects of its drug candidate, Bezielle, on cancer cells in the International Journal of Cancer.

19 Jul 2011

Optimer introduces DIFICID for treatment of C. difficile-associated diarrhea

Optimer Pharmaceuticals, Inc. today announced the commercial launch of DIFICID (fidaxomicin) tablets for the treatment of Clostridium difficile-associated diarrhea (CDAD) in patients 18 years of age and older.

19 Jul 2011